Written by Aisha Saleem, Pharmacist & Health Writer at PharmaHealths.com
Last Updated: August 2026
One of the most distressing aspects of living with eczema, particularly for people with moderate-to-severe disease, is what happens to the skin between and after flares. The itch scratch cycle, repeated inflammation, and skin barrier disruption leave visible marks that persist long after the active flare has settled. Patients frequently ask whether these marks are permanent scars, whether they will fade, and whether anything can be done to accelerate their resolution.
The honest answer depends on which type of mark is present, because eczema produces several distinct types of skin change, and they behave very differently from one another.
Does Eczema Actually Cause Scarring?
True scarring, the formation of fibrous scar tissue replacing normal skin architecture, is not the most common outcome of eczema flares. Eczema primarily causes post inflammatory skin changes rather than structural scarring in the way that deep wounds or surgical incisions do.
However, eczema can cause true scarring under specific circumstances, most commonly from secondary bacterial infection, from extremely deep or prolonged scratching that breaches the dermis, or from interventions like injudicious use of topical treatments. The distinction matters because true scars are permanent and require different management from post inflammatory changes, which are reversible.
The three main types of skin change left by eczema are post inflammatory hyperpigmentation, post inflammatory hypopigmentation, and lichenification, all of which are frequently mistaken for permanent scarring but are not the same thing.
Post Inflammatory Hyperpigmentation (PIH)
Post inflammatory hyperpigmentation is the most common mark left by eczema. It appears as flat, darkened patches of skin, ranging from light brown to deep brown or grey black, at sites of previous inflammation. It occurs because skin inflammation triggers melanocytes, the pigment producing cells, to increase melanin production in the affected area. As the inflammation resolves, the excess melanin remains in the skin, producing visible discoloration.
PIH is not a scar in the structural sense. The skin architecture is intact; no fibrous tissue has formed. The discoloration is confined to the epidermis or superficial dermis and will fade over time, though the timeline varies significantly.
PIH is considerably more pronounced and more persistent in people with darker skin tones, Fitzpatrick skin types IV to VI. Research published in the Journal of Clinical and Aesthetic Dermatology confirmed that post inflammatory hyperpigmentation causes disproportionate psychological distress in patients with darker skin, and that the marks can persist for 12 months or longer without active treatment. This is a clinically significant disparity that is underrepresented in mainstream eczema guidance.
Post Inflammatory Hypopigmentation
Less commonly, eczema flares leave areas of lighter skin rather than darker. Post inflammatory hypopigmentation occurs when inflammation damages melanocytes, temporarily reducing their ability to produce melanin. This is more commonly seen after topical corticosteroid use, which can suppress melanocyte activity in addition to its anti-inflammatory effects, particularly with potent corticosteroids applied for prolonged periods to thin skin.
Hypopigmentation from eczema is almost always temporary. Melanocyte function recovers as the skin heals and inflammation subsides, though full repigmentation can take several months. Distinguishing post inflammatory hypopigmentation from vitiligo, a separate autoimmune condition causing permanent melanocyte loss, requires clinical assessment. In vitiligo, the depigmentation is typically sharply bordered, symmetrical, and does not correlate with previous eczema sites.
Lichenification
Lichenification is the thickening and hardening of skin that develops in response to chronic scratching and rubbing. It is one of the most recognizable features of long-standing eczema. The skin takes on a leathery texture, with accentuated skin markings, the normal fine lines of the skin become exaggerated and visible as a criss cross pattern. Lichenified skin is typically darker than surrounding skin and intensely itchy, a feature that perpetuates the scratch lichenification cycle.
Unlike post inflammatory pigmentation changes, lichenification involves actual structural changes to the skin, epidermal thickening, altered dermal collagen deposition, and changes in nerve fiber density that contribute to the intense itch. Research published in the British Journal of Dermatology has documented increased density of substance P-containing nerve fibers in lichenified eczema skin, which directly amplifies itch signaling.
Lichenification is reversible with consistent eczema treatment and cessation of scratching. Topical corticosteroids reduce inflammation and allow the thickened skin to soften over weeks to months. In severe or recalcitrant lichenification, occlusive dressings, wet wrap therapy, accelerate penetration of topical treatments and promote skin softening.
True Scarring in Eczema: When Does It Occur?
3 to 5% of eczema patients develop true dermal scarring, primarily in the context of secondary bacterial infection, most commonly Staphylococcus aureus, which causes deeper tissue involvement than the primary eczema inflammation. Skin that has been scratched deeply and repeatedly to the point of bleeding and crusting over extended periods carries the highest risk of structural scarring.
Infection related eczema scarring typically presents as atrophic (depressed, pitted) scars, similar to those seen in severe acne, rather than raised or hypertrophic scars. This distinction is relevant to treatment planning.
How Long Do Eczema Marks Take to Fade?
Post inflammatory hyperpigmentation on lighter skin tones typically fades within 3 to 6 months without active treatment, provided the underlying eczema is well controlled and further inflammation does not occur at the site. On darker skin tones, Fitzpatrick types IV to VI, PIH can persist for 12 to 24 months or longer without targeted intervention.
Hypopigmentation generally resolves within 3 to 6 months as melanocyte function recovers following inflammation.
Lichenification softens progressively over 4 to 8 weeks of consistent topical corticosteroid use once active inflammation is controlled, with full resolution possible over several months in most patients.
True dermal scarring does not resolve spontaneously. It requires specific dermatological intervention if treatment is desired.
Eczema Scarring on Darker Skin Tones
The impact of eczema related pigmentation changes is disproportionately severe in people with darker skin tones, and this disparity is insufficiently recognized in standard eczema management guidance. PIH is more intense, covers larger areas, and persists significantly longer in Fitzpatrick types IV to VI. In some patients, the post inflammatory marks cause more distress than the active eczema itself.
A study published in the Journal of the American Academy of Dermatology found that Black patients with atopic dermatitis reported significantly higher rates of psychosocial distress related to skin discoloration and scarring compared to white patients with equivalent disease severity scores, highlighting the need for clinicians to specifically address pigmentation management alongside standard eczema treatment.
Effective eczema control, reducing the frequency and severity of flares, is the single most impactful intervention for preventing PIH progression in darker skin tones. Photoprotection with broad-spectrum SPF 30 or above is critical, UV exposure significantly darkens and prolongs PIH regardless of skin tone.
How to Fade Eczema Marks and Hyperpigmentation
Fading post inflammatory hyperpigmentation requires a two-pronged approach, controlling the underlying eczema to prevent new pigmentation events, and applying targeted depigmenting agents to the marks already present.
Niacinamide
Niacinamide at 4–5% concentration inhibits the transfer of melanosomes, melanin containing vesicles, from melanocytes to surrounding keratinocytes, reducing the visible pigmentation of PIH. It simultaneously supports ceramide synthesis and barrier function, making it particularly appropriate for eczema-prone skin. A randomized controlled trial published in the British Journal of Dermatology demonstrated that 4% niacinamide significantly reduced facial hyperpigmentation over 8 weeks compared to vehicle. It is well tolerated on sensitized skin and is a logical first line topical agent for eczema-associated PIH.
Vitamin C (L-ascorbic acid)
Vitamin C inhibits tyrosinase, the enzyme responsible for melanin synthesis, and reduces oxidative stress in pigmented skin. At concentrations of 10–20%, it is an effective depigmenting agent. The main limitation for eczema skin is that standard vitamin C formulations are unstable and can be irritating on barrier-compromised skin. More stable derivatives, ascorbyl glucoside, sodium ascorbyl phosphate, are better tolerated on sensitized skin and appropriate to introduce once the barrier is restored.
Azelaic Acid
Azelaic acid at 10–20% inhibits tyrosinase and selectively targets hyperactive melanocytes without affecting normal pigmentation. It has a strong safety profile, is anti-inflammatory, and is suitable for all skin tones. A review published in Dermatologic Therapy confirmed its efficacy in PIH across Fitzpatrick skin types II to VI. It is particularly useful in eczema-prone skin because of its combined anti-inflammatory and depigmenting action.
Sunscreen
Broad spectrum SPF 30 or above is non-negotiable when treating eczema associated PIH. UV exposure stimulates further melanin production and significantly prolongs the fading timeline. A mineral sunscreen, zinc oxide or titanium dioxide, is better tolerated on eczema-prone skin than chemical UV filters, which can cause stinging and irritation on a compromised barrier.
Retinoids
Topical retinoids, retinol, retinaldehyde, prescription tretinoin, accelerate cell turnover, moving pigmented cells out of the epidermis more rapidly and reducing the intensity of PIH over time. The main challenge in eczema skin is the retinoid adjustment phase, initial dryness, peeling, and irritation can compound barrier damage. Retinoids should only be introduced once the skin barrier is restored, starting at low concentrations two nights per week and building gradually. I have covered skin barrier repair in a separate article on PharmaHealths.
What Cannot Be Treated Topically
True dermal scarring, atrophic, pitted scars from secondary infection or deep skin damage, does not respond to topical depigmenting agents. Treatment options in this category include:
• Microneedling, promotes collagen remodeling in atrophic scars; requires a clinical setting
• Fractional laser resurfacing, effective for atrophic scarring but requires skin to be fully in remission before treatment; must be performed by a dermatologist experienced in treating eczema-prone skin
• Silicone gel, evidence supported for hypertrophic and keloid scar management; limited evidence in eczema specific scarring
Any of these should be discussed with a dermatologist rather than pursued through non-clinical providers.
Will Eczema Marks Fade on Their Own in Children?
In children, post inflammatory pigmentation changes typically resolve more rapidly than in adults, because higher cell turnover rates in younger skin move pigmented cells out of the epidermis more quickly. Most PIH in children with well-controlled eczema fades within 3 to 6 months without active treatment. Lichenification in children also responds faster to topical corticosteroid treatment than in adults.
The most important intervention in children is consistent eczema control, every additional flare at a pigmented site reactivates melanocyte stimulation and resets the fading timeline. Sun protection is equally important in children; even incidental UV exposure prolongs PIH significantly.
Conclusion
Eczema rarely causes the true structural scarring that people fear most, but it consistently leaves post inflammatory marks that can be persistent, distressing, and significantly under addressed in standard eczema management. Post inflammatory hyperpigmentation, hypopigmentation, and lichenification are all reversible with appropriate treatment and eczema control. The fading timeline, 3 months to over 24 months depending on skin tone, underscores that consistent daily SPF use and eczema control are not optional additions to a management plan. They are the primary determinants of how quickly the skin recovers its appearance after a flare.
Disclaimer
This article is for informational purposes only and does not constitute medical advice. If you are concerned about eczema-related scarring or pigmentation changes, or if they are significantly affecting your quality of life, consult a doctor dermatologist for an individualized assessment and treatment plan.
References
• NICE — Atopic eczema in under 12s: diagnosis and management (CG57): https://www.nice.org.uk/guidance/cg57
• NHS — Atopic eczema: https://www.nhs.uk/conditions/atopic-eczema/
• National Eczema Association — Eczema and skin of color: https://nationaleczema.org/eczema/skin-of-color/
• Kaufman BP et al. Atopic dermatitis in diverse racial and ethnic groups — variations in epidemiology, genetics, clinical presentation and treatment. Experimental Dermatology. 2018: https://onlinelibrary.wiley.com/doi/10.1111/exd.13514
• Alexis AF et al. Racial and ethnic differences in self-assessed features of atopic dermatitis and its psychological impact. Journal of the American Academy of Dermatology. 2019: https://www.jaad.org/article/S0190-9622(19)30303-7/fulltext
• Rawlings AV. Ethnic skin types: are there differences in skin structure and function? International Journal of Cosmetic Science. 2006: https://onlinelibrary.wiley.com/doi/10.1111/j.1467-2494.2006.00324.x
• Bissett DL, Oblong JE, Berge CA. Niacinamide: a B vitamin that improves ageing facial skin appearance. Dermatologic Surgery. 2005: https://onlinelibrary.wiley.com/doi/10.1111/j.1524-4725.2005.31822
• Hakozaki T et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. British Journal of Dermatology. 2002: https://academic.oup.com/bjd/article/147/1/20/6686583
• Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatologic Therapy. 2007: https://onlinelibrary.wiley.com/doi/10.1111/j.1529-8019.2007.00106.x
• Fitton A, Goa KL. Azelaic acid: a review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs. 1991: https://link.springer.com/article/10.2165/00003495-199141050-00007
• Telang PS. Vitamin C in dermatology. Indian Dermatology Online Journal. 2013: https://www.idoj.in/article.asp?issn=2229-5178;year=2013;volume=4;issue=2;spage=143;epage=146;aulast=Telang
• Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. The Lancet. 2020: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31286-1/fulltext
• Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea. F1000Research. 2018 — cited for nerve fiber density and itch amplification in lichenified skin: https://f1000research.com/articles/7-1885/v1
• British Association of Dermatologists — Atopic Eczema Patient Information Leaflet: https://www.bad.org.uk/pils/atopic-eczema/
